• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Section 32 Raises $740 Million Venture Fund

    11/4/21 8:14:00 AM ET
    $COIN
    $CRWD
    $EXAS
    $RLAY
    Finance: Consumer Services
    Finance
    Computer Software: Prepackaged Software
    Technology
    Get the next $COIN alert in real time by email

    SAN DIEGO, Nov. 4, 2021 /PRNewswire/ -- Section 32 announced today the closing of its fourth fund, raising approximately $740 million from returning and new investors. Investors in Fund 4 include leading philanthropic and non-profit organizations, educational endowments and foundations, and leaders from the technology and healthcare sectors. Section 32 Fund 4 will support companies across all stages that are pioneering innovations at the forefront of technology and healthcare. With the closing of its oversubscribed Fund 4 and to support its continued growth, Section 32 also announced the appointment of Nina Labatt to the role of Chief Operating Officer and Chief Financial Officer.

    Section 32 is a venture capital fund investing at the frontiers of technology and healthcare.

    "I'm so pleased that Nina has joined this team and I look forward to what this growing group will achieve together," commented Bill Maris, founder of Section 32. "What a privilege it is to close this fourth fund, and to thus have the continued opportunity to try to use capital as a lever to accelerate the profound positive impact technology can have on healthcare and humanity."

    The closing of Fund 4 brings assets under management for Section 32 to over $1.8B. To-date, Section 32 has made investments in more than 70 companies including Coinbase (NASDAQ:COIN), Crowdstrike (NASDAQ:CRWD), Relay Therapeutics (NASDAQ:RLAY), Thrive Earlier Detection (NASDAQ:EXAS), and Vir Biotechnology (NASDAQ:VIR). Section 32 has made eight investments from Fund 4 following an initial close of the fund in July 2021.

    Since its inception in 2017, Section 32 has grown to 16 people, including four managing partners: Bill Maris, Michael Pellini, M.D., Steve Kafka, Ph.D., and Andy Harrison, with offices in San Diego, Silicon Valley and Boston, MA. The team's cumulative career experience includes contributing to more than 130 company exits (through acquisition or public offerings) and helping to build and finance more than 50 companies with valuations in excess of $1 billion.

    With the closing of Fund 4, Section 32 added Nina Labatt to its team as its chief operating officer and chief financial officer. Nina brings more than two decades of experience to her new role and is recognized as an industry expert leading finance and operations in venture capital and private equity.

    "I'm delighted to join the team at Section 32 at this exciting time in the firm's growth," commented Nina Labatt. "I look forward to collaborating with the team to continue building world-class operations and finance functions that support our investing efforts."

    Most recently, Nina served as chief operating officer and general partner at Trinity Ventures, where she managed finance, marketing, data analytics, human resources, and legal for the firm. She also led internal strategic initiatives, structured and executed investment transactions with the investing team and participated in the firm's fundraising efforts. Previously, Ms. Labatt served as managing director, Private Equity Services for Silicon Valley Bank, as well as chief financial officer for Health Evolution Partners. Earlier in her career, Ms. Labatt was an investment banker for Goldman Sachs and Montgomery Securities. Ms. Labatt received a bachelor's degree in economics and a master's degree in international policy studies from Stanford University. She received her MBA from Harvard Business School. She was a founding member of the Northern California board of directors for the CFO Leadership Council and previously served as chairperson of the board of directors of VCBC, a non-profit association for finance professionals in venture capital.

    About Section 32

    Section 32 is a venture capital fund investing at the frontiers of technology and healthcare. Founded by Bill Maris, the team has vast experience building iconic companies. The firm's goal is to improve the human condition by accelerating the discovery, development and distribution of important technologies and life-saving medicines. Section 32 invests across the entirety of technology and life sciences. This includes software, cybersecurity, advanced communications and computation, space, climate change related technologies, machine learning, artificial intelligence, biotechnology, therapeutics, advanced diagnostics, precision medicine, genomics and more. For more information, please visit Section32.com

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/section-32-raises-740-million-venture-fund-301416494.html

    SOURCE Section 32

    Get the next $COIN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $COIN
    $CRWD
    $EXAS
    $RLAY

    CompanyDatePrice TargetRatingAnalyst
    Relay Therapeutics Inc.
    $RLAY
    9/4/2025$15.00Buy
    Guggenheim
    Vir Biotechnology Inc.
    $VIR
    9/3/2025$12.00Outperform
    Evercore ISI
    Vir Biotechnology Inc.
    $VIR
    8/27/2025$14.00Neutral → Buy
    BofA Securities
    CrowdStrike Holdings Inc.
    $CRWD
    8/25/2025$500.00 → $460.00Outperform
    BMO Capital Markets
    CrowdStrike Holdings Inc.
    $CRWD
    8/18/2025$440.00 → $425.00In-line
    Evercore ISI
    Coinbase Global Inc.
    $COIN
    8/4/2025$248.00Neutral → Sell
    Compass Point
    Coinbase Global Inc.
    $COIN
    7/28/2025Buy → Neutral
    Monness Crespi & Hardt
    Coinbase Global Inc.
    $COIN
    7/23/2025Buy
    Erste Group
    More analyst ratings

    $COIN
    $CRWD
    $EXAS
    $RLAY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CrowdStrike and Amazon Business Prime Transform Cybersecurity for Small Businesses

    New collaboration makes AI-native protection accessible, affordable, and easy to manage for Business Prime members on Essentials, Small, Medium, and Enterprise plans CrowdStrike (NASDAQ:CRWD) today announced a strategic collaboration with Business Prime that makes world-class cybersecurity available to small and medium businesses (SMBs) at no cost. Starting immediately, Business Prime Essentials, Small, Medium, and Enterprise members are eligible for CrowdStrike Falcon® Go – the industry's award-winning AI-powered cybersecurity platform purpose-built for SMBs – as a free benefit of their paid membership, a savings of $59.99 per device/per month. Business Prime Duo members are eligible for

    9/10/25 8:00:00 AM ET
    $CRWD
    Computer Software: Prepackaged Software
    Technology

    Exact Sciences Launches Cancerguard™, First-of-Its-Kind Multi-Cancer Early Detection Blood Test

    Only MCED test on-market to analyze multiple biomarker classes, enhancing early cancer detection Offered as a laboratory-developed test at $689 Nationwide access enabled through Quest Diagnostics' 7,000 patient access sites Exact Sciences Corp. (NASDAQ:EXAS), a leader in cancer diagnostics, today announced the launch of the Cancerguard™ test, a new multi-cancer early detection (MCED) blood test that is now available as a laboratory-developed test (LDT) in the United States. Cancerguard is the first MCED test commercially available that analyzes multiple biomarker classes to help detect a wide range of cancers, including those that often go undiagnosed until later stages when treatment

    9/10/25 6:30:00 AM ET
    $EXAS
    Medical Specialities
    Health Care

    Fal.Con 2025: CrowdStrike and Partners Define the Future of Security Through Ecosystem Innovation

    A record-breaking partner network joins forces with CrowdStrike to innovate with AI, secure AI, and deliver stronger outcomes – proving the unmatched strength of the Crowd CrowdStrike (NASDAQ:CRWD) today announced that Fal.Con 2025 will feature a record 115+ sponsors, led by Amazon Web Services (AWS), Dell Technologies, Google Cloud, Intel, NVIDIA, and Salesforce. The four-day conference has reached capacity with more than 8,000+ attendees from 3,000 organizations across 65 countries. Major systems integrators Accenture, Deloitte, and EY will demonstrate how customers achieve breakthrough security outcomes on the CrowdStrike Falcon® platform. "When this many industry leaders choose th

    9/8/25 8:00:00 AM ET
    $CRWD
    Computer Software: Prepackaged Software
    Technology

    $COIN
    $CRWD
    $EXAS
    $RLAY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Conroy Kevin T bought $1,001,325 worth of shares (19,500 units at $51.35), increasing direct ownership by 2% to 1,074,191 units (SEC Form 4)

    4 - EXACT SCIENCES CORP (0001124140) (Issuer)

    11/13/24 12:56:28 PM ET
    $EXAS
    Medical Specialities
    Health Care

    $COIN
    $CRWD
    $EXAS
    $RLAY
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Exact Sciences Corporation

    SCHEDULE 13G/A - EXACT SCIENCES CORP (0001124140) (Subject)

    9/8/25 11:46:16 AM ET
    $EXAS
    Medical Specialities
    Health Care

    SEC Form 144 filed by CrowdStrike Holdings Inc.

    144 - CrowdStrike Holdings, Inc. (0001535527) (Subject)

    9/4/25 5:05:07 PM ET
    $CRWD
    Computer Software: Prepackaged Software
    Technology

    SEC Form 10-Q filed by CrowdStrike Holdings Inc.

    10-Q - CrowdStrike Holdings, Inc. (0001535527) (Filer)

    8/27/25 9:43:28 PM ET
    $CRWD
    Computer Software: Prepackaged Software
    Technology

    $COIN
    $CRWD
    $EXAS
    $RLAY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim resumed coverage on Relay Therapeutics with a new price target

    Guggenheim resumed coverage of Relay Therapeutics with a rating of Buy and set a new price target of $15.00

    9/4/25 9:07:32 AM ET
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Evercore ISI initiated coverage on Vir Biotechnology with a new price target

    Evercore ISI initiated coverage of Vir Biotechnology with a rating of Outperform and set a new price target of $12.00

    9/3/25 8:41:05 AM ET
    $VIR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vir Biotechnology upgraded by BofA Securities with a new price target

    BofA Securities upgraded Vir Biotechnology from Neutral to Buy and set a new price target of $14.00

    8/27/25 8:18:54 AM ET
    $VIR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $COIN
    $CRWD
    $EXAS
    $RLAY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Gandhi Sameer K sold $2,564,478 worth of shares (6,250 units at $410.32) (SEC Form 4)

    4 - CrowdStrike Holdings, Inc. (0001535527) (Issuer)

    9/8/25 8:30:05 PM ET
    $CRWD
    Computer Software: Prepackaged Software
    Technology

    Chairman and CEO Armstrong Brian converted options into 25,000 shares and sold $7,554,679 worth of shares (25,000 units at $302.19) (SEC Form 4)

    4 - Coinbase Global, Inc. (0001679788) (Issuer)

    9/8/25 4:21:10 PM ET
    $COIN
    Finance: Consumer Services
    Finance

    Chief Legal Officer Grewal Paul exercised 10,000 shares at a strike of $26.26 and sold $3,045,196 worth of shares (10,000 units at $304.52) (SEC Form 4)

    4 - Coinbase Global, Inc. (0001679788) (Issuer)

    9/4/25 5:17:53 PM ET
    $COIN
    Finance: Consumer Services
    Finance

    $COIN
    $CRWD
    $EXAS
    $RLAY
    Financials

    Live finance-specific insights

    View All

    CrowdStrike Reports Second Quarter Fiscal Year 2026 Financial Results

    Achieves record Q2 net new ARR of $221 million and reacceleration ahead of expectations Ending ARR grows 20% year-over-year to reach $4.66 billion Delivers record Q2 cash flow from operations of $333 million and record Q2 free cash flow of $284 million CrowdStrike Holdings, Inc. (NASDAQ:CRWD), today announced financial results for the second quarter fiscal year 2026, ended July 31, 2025. "With reacceleration a quarter ahead of our expectations, CrowdStrike delivered an exceptional Q2. Record Q2 net new ARR of $221 million, over 1,000 Flex customers, and more than 100 re-flexes highlight CrowdStrike as the leader in cybersecurity consolidation," said George Kurtz, Founder and CEO

    8/27/25 4:10:00 PM ET
    $CRWD
    Computer Software: Prepackaged Software
    Technology

    Exact Sciences Announces Second Quarter 2025 Results

    Reports record revenue, improves adjusted EBITDA, raises full-year guidance Second quarter and recent highlights Delivered record total second quarter revenue of $811 million, an increase of 16% on a reported and core revenue basis, including Screening revenue of $628 million and Precision Oncology revenue of $183 million Raised full-year 2025 revenue and adjusted EBITDA guidance midpoints by $55 million and $25 million, respectively Entered into an exclusive license agreement with Freenome for blood-based colorectal cancer screening tests Gained Medicare coverage for Oncodetect™ molecular residual disease and recurrence monitoring test Announced a multi-year productivity p

    8/6/25 4:05:00 PM ET
    $EXAS
    Medical Specialities
    Health Care

    Exact Sciences Announces Exclusive License with Freenome for Blood-Based Colorectal Cancer Screening Tests

    Exact Sciences acquires exclusive rights to current and future versions of Freenome's blood-based colorectal cancer screening tests Freenome submitted the final module of the premarket approval application to the FDA for the first-version test Strengthens Exact Sciences' leadership in colorectal cancer screening by adding blood-based testing to complement Cologuard Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, and Freenome, a biotechnology company pioneering an early cancer detection platform, today announced they have entered into an agreement under which Exact Sciences will acquire exclusive rights in the United States to current an

    8/6/25 4:05:00 PM ET
    $EXAS
    Medical Specialities
    Health Care

    $COIN
    $CRWD
    $EXAS
    $RLAY
    Leadership Updates

    Live Leadership Updates

    View All

    Dataminr Appoints Tiffany Buchanan as Chief Financial Officer to Accelerate Strategic Growth and Public Market Readiness

    Former CrowdStrike finance leader brings deep expertise in scaling high-growth technology companies, and will partner with Dataminr's leadership team to drive global expansion and operational scale  NEW YORK, June 26, 2025 /PRNewswire/ -- Dataminr, the leading real-time AI platform, today announced the appointment of Tiffany Buchanan as Chief Financial Officer. Buchanan is a highly accomplished executive with a proven track record of accelerating growth, leading IPO readiness, and operating at scale in the public market. Drawing upon more than 20 years of experience leading g

    6/26/25 9:00:00 AM ET
    $CRWD
    Computer Software: Prepackaged Software
    Technology

    Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors

    CAMBRIDGE, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced the appointment of Claire Mazumdar, Ph.D., to the Company's Board of Directors, effective June 9, 2025. "It is a privilege to welcome Claire to our Board, where she will draw from her strategic and operational experience in clinical-stage oncology to offer guidance as we prepare to initiate our Phase 3 ReDiscover-2 trial in breast cancer soon," said Sanjiv Patel, M.D., President and Chief Executive Officer of Relay Therapeutics.

    6/11/25 4:05:00 PM ET
    $BCAX
    $RLAY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    CrowdStrike Appoints Brad Burns as Chief Communications Officer

    Former Salesforce and Snowflake CCO to drive comms strategy for CrowdStrike's next phase of growth and innovation CrowdStrike (NASDAQ:CRWD) today announced the appointment of Brad Burns as chief communications officer (CCO). Burns will lead the company's global communications strategy, supporting executive leadership as CrowdStrike accelerates its growth and scale as cybersecurity's platform innovator for the AI era. "CrowdStrike's mission to stop breaches has never been more important. As adversaries weaponize AI – lowering the bar to launch and scale attacks – communicating the power of the Falcon platform to defeat modern threats is critical to businesses around the world," said George

    5/13/25 8:01:00 AM ET
    $CRWD
    Computer Software: Prepackaged Software
    Technology

    $COIN
    $CRWD
    $EXAS
    $RLAY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Coinbase Global Inc.

    SC 13G/A - Coinbase Global, Inc. (0001679788) (Subject)

    11/14/24 5:44:24 PM ET
    $COIN
    Finance: Consumer Services
    Finance

    Amendment: SEC Form SC 13G/A filed by Coinbase Global Inc.

    SC 13G/A - Coinbase Global, Inc. (0001679788) (Subject)

    11/14/24 5:40:50 PM ET
    $COIN
    Finance: Consumer Services
    Finance

    Amendment: SEC Form SC 13G/A filed by CrowdStrike Holdings Inc.

    SC 13G/A - CrowdStrike Holdings, Inc. (0001535527) (Subject)

    11/14/24 1:22:38 PM ET
    $CRWD
    Computer Software: Prepackaged Software
    Technology